• <a fr-original-style="" href="https://time.com/6244798/fda-approves-lecanemab-alzheimers-drug/" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank">Eisai and Biogen</a> on Friday gained US approval for their Alzheimer's drug lecanemab, developed for patients in the earliest stages of the mind-wasting disease. The US Food and Drug Administration approved the drug —which will be sold under the brand Leqembi— via the <a fr-original-style="" href="https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank">Accelerated Approval</a> pathway. The companies said on Saturday the Japanese drugmaker had also applied for full FDA approval of the drug.<img src="https://images.aposto.com/2023/0/0/1673196488637.png" style="display: block; float: none; vertical-align: top; margin: 5px auto; text-align: center; width: 100%; max-width: 550px; border-style: none; position: relative; cursor: pointer; padding: 0px 1px; box-sizing: border-box;" ratio="1.40" width="550" alt="Leqembi" fr-original-style="display: block; float: none; vertical-align: top; margin: 5px auto; text-align: center; width: 100%; max-width: 550px;" fr-original-class="fr-draggable">Eisai<ul fr-original-style="padding-inline-start: 20px;" style="padding-inline-start: 20px; margin-top: 0px; margin-bottom: 1em; list-style-position: inside; box-sizing: border-box;"><li fr-original-style="" style="box-sizing: border-box;">Zoom in: The drug belongs to a class of treatments that aim to slow the advance of the neurodegenerative disease by removing sticky clumps of the toxic protein beta-amyloid from the brain. Nearly all previous experimental drugs using the same approach had failed. <a fr-original-style="" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-eisai-biogens-alzheimers-drug-2023-01-06/" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank">Eisai said</a> the drug would launch at an annual price of $26,500.</li></ul>

-amyloid ile ilgili hikayeler